Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Rudzinski (Warsaw, Poland), A. Szpechcinski (Warsaw, Poland), J. Moes-Sosnowska (Warsaw, Poland), K. Duk (Warsaw, Poland), A. Zdral (Warsaw, Poland), U. Lechowicz (Warsaw, Poland), P. Rudzinski (Warsaw, Poland), W. Kupis (Warsaw, Poland), E. Szczepulska-Wójcik (Warsaw, Poland), R. Langfort (Warsaw, Poland), T. Orlowski (Warsaw, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros. 4059

Member's Comments

No comment yet.

Related content which might interest you: Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Next-generation sequencing and assessment of tumour mutational burden: are these tools ready for clinical routine use? Source: International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas Year: 2019 Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression – NGS pilot study. Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Late Breaking Abstract: Real-time PCR versus direct sequencing in detection of EGFR T790M and L858R mutations – The sensitivity comparison Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010 The real challenges in next generation sequencing for solid tumors Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014 Immunohistochemistry versus DNA testing for detection of EGFR mutations and ALK rearrangements in lung adenocarcinoma patients Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in various types of clinical non-small cell lung cancer specimens Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Detection of rifampin resistance mutations in Mycobacterium tuberculosis by use of sequencing, molecular beacons and taqman probes Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009 Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Treatment sequencing in NSCLC EGFR+ – real-world data Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Diagnostic utility of PNA-LNA PCR clamp method for detection of EGFR exon 19 deletions and exon 21 codon L858 mutations in NSCLC samples with low tumor cells content Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Screening strategies pros and cons Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early Year: 2004 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 LATE-BREAKING ABSTRACT: Novel rapid screening assay for HER2 duplicated insertion mutation by Eprobe-PCR method Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016